Summation Bio is a gene therapy company developing a novel non-viral gene transfer technology. Summation’s Mini-nucleosome technology addresses the unmet needs in specifically delivering large-sized DNA/RNA to multiple cell types. The Mini-nucleosome technology has the power to enable efficient, regulated and safe DNA/RNA/RNAi delivery, gene/base editing, antibody delivery, targeted tumor therapies, and tissue regeneration. With no limitations in packaging capacity and tissue targeting, Summation Bio is poised to demonstrate the capability of treating complex genetic and acquired diseases with its novel gene therapy vectors.